GlaxoSmithKline is close to seeking European approval for a gene therapy drug to fight adenosine deaminase severe combined immune deficiency in the latest sign of a renaissance in the technology to fix faulty genes. A uniQure bioprocessing engineer checks a monitor of a sterile disposable plastic cell culture bag as it is placed onto a rocking platform in a laboratory at Dutch biotech company uniQure in Amsterdam December 13, 2012.